Venture fund's initial investments include Lava Therapeutics, which floated on Nasdaq stock exchange in March.
Pureos Bioventures, a Switzerland-based venture capital firm backed by undisclosed strategic investors in life sciences, has extended the size of its first fund to $205m.
The final closing of BB Pureos Bioventures will target a portfolio of 17 to 20 pre-clinical and clinical-stage companies in Europe developing novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies.
Its initial investments include Lava Therapeutics (floated on Nasdaq stock exchange in March), Alentis Therapeutics, AM-Pharma, Araris, Corlieve Therapeutics,…
